Literature DB >> 9686342

In vivo measurement of ureagenesis with stable isotopes.

M Yudkoff1, Y Daikhin, X Ye, J M Wilson, M L Batshaw.   

Abstract

We have utilized stable isotopes to measure in vivo rates of ureagenesis. In one testing procedure, 15NH4Cl was administered orally to controls and to heterozygotes for ornithine transcarbamylase deficiency. Controls produced [15N]urea at a rate that was greater than that of symptomatic carriers, but indistinguishable from that of asymptomatic carriers. In contrast, both symptomatic and asymptomatic heterozygotes produced [5-15N]glutamine more rapidly than the controls. Ureagenesis could also be measured by administering sodium [1-13C]acetate to a healthy adult and measuring subsequent formation of [13C]urea. The latter approach involves the use of isotope ratio mass spectrometry to determine isotopic abundance. This technique is much more sensitive than gas chromatography-mass spectrometry for the measurement of isotopic label, a consideration that makes the method more suitable for the study of subjects in whom ureagenesis is severely compromised, for example the human male neonate with a near complete deficiency of ornithine transcarbamylase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686342     DOI: 10.1023/a:1005345205403

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

1.  In vivo nitrogen metabolism in ornithine transcarbamylase deficiency.

Authors:  M Yudkoff; Y Daikhin; I Nissim; A Jawad; J Wilson; M Batshaw
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

2.  Studies of X-chromosome inactivation with an improved histochemical technique for ornithine carbamoyltransferase.

Authors:  K A Wareham; S Howell; D Williams; E D Williams
Journal:  Histochem J       Date:  1983-04

3.  Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector.

Authors:  L D Stratford-Perricaudet; M Levrero; J F Chasse; M Perricaudet; P Briand
Journal:  Hum Gene Ther       Date:  1990       Impact factor: 5.695

4.  The biochemical and molecular spectrum of ornithine transcarbamylase deficiency.

Authors:  M Tuchman; H Morizono; B S Rajagopal; R J Plante; N M Allewell
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

5.  Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.

Authors:  S E Raper; J M Wilson; M Yudkoff; M B Robinson; X Ye; M L Batshaw
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

6.  Metabolism and recycling of urea in man.

Authors:  C L Long; M Jeevanandam; J M Kinney
Journal:  Am J Clin Nutr       Date:  1978-08       Impact factor: 7.045

7.  Measurement of urea kinetics in humans: a validation of stable isotope tracer methods.

Authors:  D E Matthews; R S Downey
Journal:  Am J Physiol       Date:  1984-06

8.  Allopurinol challenge test in children.

Authors:  A B Burlina; V Ferrari; C Dionisi-Vici; A Bordugo; F Zacchello; M Tuchman
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

9.  Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes.

Authors:  M A Morsy; E L Alford; A Bett; F L Graham; C T Caskey
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  Urea synthesis, nitrogen balance, and glucose turnover in growth-hormone-deficient children before and after growth hormone administration.

Authors:  W T Dahms; R P Owens; S C Kalhan; D S Kerr; R K Danish
Journal:  Metabolism       Date:  1989-03       Impact factor: 8.694

View more
  8 in total

1.  Measuring in vivo ureagenesis with stable isotopes.

Authors:  Marc Yudkoff; Nicholas Ah Mew; Yevgeny Daikhin; Oksana Horyn; Ilana Nissim; Itzhak Nissim; Irma Payan; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2010-02-26       Impact factor: 4.797

2.  Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions.

Authors:  Corinne Inauen; Véronique Rüfenacht; Amit V Pandey; Liyan Hu; Henk Blom; Jean-Marc Nuoffer; Johannes Häberle
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

3.  Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.

Authors:  S E Raper; J M Wilson; M Yudkoff; M B Robinson; X Ye; M L Batshaw
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

4.  Long-term outcome of patients with urea cycle disorders and the question of neonatal screening.

Authors:  Claude Bachmann
Journal:  Eur J Pediatr       Date:  2003-11-21       Impact factor: 3.183

5.  How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency?

Authors:  S Grünewald; L Fairbanks; S Genet; T Cranston; J Hüsing; J V Leonard; M P Champion
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

6.  Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy.

Authors:  C Hu; D S Tai; H Park; G Cantero; G Cantero-Nieto; E Chan; M Yudkoff; S D Cederbaum; G S Lipshutz
Journal:  Gene Ther       Date:  2014-12-04       Impact factor: 5.250

7.  An Algorithm Measuring Donor Cell-Free DNA in Plasma of Cellular and Solid Organ Transplant Recipients That Does Not Require Donor or Recipient Genotyping.

Authors:  Paul M K Gordon; Aneal Khan; Umair Sajid; Nicholas Chang; Varun Suresh; Leo Dimnik; Ryan E Lamont; Jillian S Parboosingh; Steven R Martin; Richard T Pon; Jene Weatherhead; Shelly Wegener; Debra Isaac; Steven C Greenway
Journal:  Front Cardiovasc Med       Date:  2016-09-22

Review 8.  Flux analysis of inborn errors of metabolism.

Authors:  D-J Reijngoud
Journal:  J Inherit Metab Dis       Date:  2018-01-09       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.